melanoma

Showing 1 - 25 of 1,172

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Profiling of Circulating Immune Cells to Uncover Response

Not yet recruiting
  • Melanoma
    • (no location specified)
    Nov 23, 2023

    Melanoma Trial (GME751, Keytruda - EU, Keytruda - US)

    Not yet recruiting
    • Melanoma
    • (no location specified)
    Nov 22, 2023

    Melanoma, NSCLC Trial (Evaluation of ctDNA using the F1T after 1 year of immunotherapy)

    Not yet recruiting
    • Melanoma
    • Non-small Cell Lung Cancer
    • Evaluation of ctDNA using the F1T after 1 year of immunotherapy
    • (no location specified)
    Nov 24, 2023

    Gut and Tumor Microbiome in Advanced ER-positive and

    Not yet recruiting
    • Breast Cancer
    • Melanoma
    • Observation
    • (no location specified)
    Nov 6, 2023

    Tumor Infiltrating Lymphocytes, Safety, Melanoma Trial in Beijing (GC101 TIL)

    Recruiting
    • Tumor Infiltrating Lymphocytes
    • +4 more
    • GC101 TIL
    • Beijing, China
      Beijing Cancer Hospital
    Nov 7, 2023

    Melanoma Trial in Rotterdam (Nivolumab)

    Recruiting
    • Melanoma
    • Rotterdam, Pending, Netherlands
      Erasmus MC
    Oct 30, 2023

    Melanoma Trial in Worldwide (relatlimab+nivolumab, relatlimab+nivolumab+rHuPH20, nivolumab)

    Not yet recruiting
    • Melanoma
    • Anchorage, Alaska
    • +28 more
    Oct 20, 2023

    NSCLC, Renal Cell Carcinoma, Melanoma Trial (Pembrolizumab co-formulated with hyaluronidase, Pembrolizumab)

    Not yet recruiting
    • Non-Small Cell Lung Cancer
    • +2 more
    • Pembrolizumab co-formulated with hyaluronidase
    • Pembrolizumab
    • (no location specified)
    Oct 19, 2023

    Advanced Solid Tumor, CDKN2A, NSCLC Trial (Milademetan, Atezolizumab)

    Withdrawn
    • Advanced Solid Tumor
    • +9 more
    • (no location specified)
    Oct 16, 2023

    Melanoma Trial in Beijing (IBI363)

    Not yet recruiting
    • Melanoma
    • IBI363
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    Oct 7, 2023

    Skin Cancer, Melanoma Trial in Stockholm (AI assistance)

    Enrolling by invitation
    • Skin Cancer
    • Melanoma
    • AI assistance
    • Stockholm, Sweden
      Karolinska University Hospital
    Oct 6, 2023

    Tumor Skin, Metastatic Melanoma, Melanoma Trial in Orlando, Louisville (OBX-115)

    Active, not recruiting
    • Tumor Skin
    • +2 more
    • OBX-115
    • Orlando, Florida
    • +1 more
    Sep 28, 2023

    Melanoma Trial (ABP 206, Nivolumab)

    Not yet recruiting
    • Melanoma
    • (no location specified)
    Sep 20, 2023

    Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult Trial (NEO212 Oral Capsule, Ipilimumab,

    Not yet recruiting
    • Diffuse Astrocytoma, IDH-Mutant
    • +20 more
    • NEO212 Oral Capsule
    • +8 more
    • (no location specified)
    Sep 18, 2023

    3 in Vivo Microscopic Imaging Techniques for Diagnosis of

    Completed
    • Basal Cell Carcinoma
    • +5 more
    • Fluorescence-Advanced videodermatoscopy
    • +2 more
    • Saint Etienne, France
      Chu de Saint Etienne
    Sep 14, 2023

    Melanoma, Breast Cancer, Oncology Trial in Saint-Petersburg

    Active, not recruiting
    • Melanoma
    • +7 more
      • Saint-Petersburg, Russian Federation
        N. N. Petrov Research Institute of oncology
      Sep 12, 2023

      Non Small Cell Lung Cancer, Hepatocellular Carcinoma, Melanoma Trial in United States (MT-8421, Nivolumab)

      Recruiting
      • Non Small Cell Lung Cancer
      • +10 more
      • Los Angeles, California
      • +4 more
      Sep 5, 2023

      ful Mutations in Solid Tumor Characterized by Next Generation

      Recruiting
      • Solid Tumor
      • +13 more
        • Aviano, Pordonone, Italy
          IRCCS, Centro di Riferimento Oncologico (CRO) di Aviano
        Sep 8, 2023

        Melanoma Trial in Beijing (tunlametinib, paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin)

        Not yet recruiting
        • Melanoma
        • tunlametinib
        • paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin
        • Beijing, Beijing, China
          Beijing Cancer Hospital
        Aug 15, 2023

        Melanoma Trial (Fluzoparib Camrelizumab Temozolomide)

        Not yet recruiting
        • Melanoma
        • Fluzoparib Camrelizumab Temozolomide
        • (no location specified)
        Aug 9, 2023

        Head Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma Trial in Scottsdale, Chapel Hill (TSC-204-A0201, TSC-204-C0702,

        Not yet recruiting
        • Head and Neck Cancer
        • +20 more
        • TSC-204-A0201
        • +4 more
        • Scottsdale, Arizona
        • +1 more
        Aug 3, 2023

        Sarcoma, Carcinoma, Digestive Cancer Trial in Linyi (Recombinant oncolytic herpes simplex virus type 1 (R130))

        Recruiting
        • Sarcoma
        • +9 more
        • Recombinant oncolytic herpes simplex virus type 1 (R130)
        • Linyi, Shandong, China
          Linyi Central Hospital
        Jul 25, 2023

        Head Neck Cancer, Cervical Cancer, Endometrial Cancer Trial (ILB-2109, Toripalimab)

        Not yet recruiting
        • Head and Neck Cancer
        • +9 more
        • (no location specified)
        Jul 12, 2023

        Melanoma Trial (V940, Pembrolizumab, Placebo)

        Not yet recruiting
        • Melanoma
        • V940
        • +2 more
        • (no location specified)
        Jul 12, 2023

        Melanoma Trial in Worldwide (encorafenib, binimetinib, pembrolizumab)

        Recruiting
        • Melanoma
        • Siena, Toscana, Italy
        • +11 more
        Jun 23, 2023